Joseph M Luettgen

Title: Joseph M Luettgen: Innovator in Antithrombotic Research

Introduction

Joseph M Luettgen is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for factor XIa. His work is crucial in advancing therapeutic options for patients requiring antithrombotic treatments.

Latest Patents

Joseph M Luettgen holds a patent for "Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof." This invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa and plasma kallikrein. The patent further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering a pharmaceutically effective dose of the antigen binding peptides. Additionally, it includes detection reagents and methods for detecting the level of FXIa inhibitors in biological samples.

Career Highlights

Joseph M Luettgen is associated with Bristol-Myers Squibb Company, where he applies his expertise in biochemistry and pharmacology. His work at this leading pharmaceutical company has positioned him as a key player in the development of innovative therapies.

Collaborations

Throughout his career, Joseph has collaborated with esteemed colleagues, including Lumelle A Schneeweis and Ginger Chao Rakestraw. These collaborations have fostered a productive environment for research and development in the field of antithrombotic therapies.

Conclusion

Joseph M Luettgen's contributions to the field of biochemistry, particularly through his patent on factor XIa inhibitors, highlight his role as an innovator in medical research. His work continues to impact the development of effective treatments for patients in need.